Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma.

ABSTRACT:

Background

Given the significant activity and tolerability of gemcitabine in patients with relapsed Hodgkin's lymphoma (HL), the critical role that nuclear factor kappa B (NF-kappaB) appears to play in the pathogenesis of this tumor, the ability of bortezomib to inhibit NF-kappaB activity, and laboratory studies suggesting synergistic antitumor effects of gemcitabine and bortezomib, we hypothesized that this combination would be efficacious in patients with relapsed or refractory HL.

Patients and methods

A total of 18 patients participated. Patients received 3-week cycles of bortezomib 1 mg/m(2) on days 1, 4, 8, and 11 plus gemcitabine 800 mg/m(2) on days 1 and 8.

Results

The overall response rate for all patients was 22% (95% confidence interval 3% to 42%). Three pat

SUBMITTER: Mendler JH 

PROVIDER: S-EPMC2735068 | biostudies-literature | 2008 Oct

REPOSITORIES: biostudies-literature